Publication:
Postchemotherapy robotic retroperitoneal lymph node dissection for non-seminomatous germ cell tumors in the lateral decubitus position: oncological and functional outcomes

dc.contributor.coauthorKilic, Mert
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorEsen, Barış
dc.contributor.kuauthorEsen, Tarık
dc.contributor.kuauthorKiremit, Murat Can
dc.contributor.kuauthorKordan, Yakup
dc.contributor.kuauthorKöseoğlu, Ersin
dc.contributor.kuauthorÖzkan, Arif
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:36:23Z
dc.date.issued2023
dc.description.abstractPurpose Retroperitoneal lymph node dissection (RPLND) is recommended for residual masses following chemotherapy for non-seminomatous germ cell tumors (NSGCT). Recently, aberrant recurrence patterns were reported in patients who underwent robotic RPLND. We aimed to evaluate perioperative safety in addition to functional and early oncological outcomes of postchemotherapy robotic RPLND (pcR-RPLND) for NSGCT.Methods A total of 25 patients with NSGCT who underwent a pcR-RPLND between January 2011 and June 2022 were evaluated retrospectively. Descriptive statistics were provided for demographics, clinical characteristics, intraoperative and postoperative parameters. Functional and oncological outcomes were recorded.Results The median patient age was 28.9 years (IQR 21.5-32.4). The median retroperitoneal tumor size was 2.6 cm (IQR 1.5-3.5). Intraoperative complications occurred in only one case and the open conversion rate was 12%. There were seven cases with postoperative complications (Clavien grade II: 5 and IIIa: 2). Patients were followed for a median of 33.2 months (IQR 14.8-43.0). Antegrade ejaculation was preserved in 85.7% of the patients. Two patients (8%) relapsed and both had out-of-field recurrences at unusual sites (perinephric fat and omentum). of those, one patient died (4%) of testicular cancer.Conclusion pcR-RPLND is a feasible and technically reproducible procedure with favorable perioperative morbidity, low rate of complications, and acceptable postoperative ejaculatory function. Although the recurrence rate was low (8%), recurrences were observed at unusual sites. Further studies are required to investigate any association between the robotic approach and aberrant recurrence patterns.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipEuropean Urological Scholarship Programme [S-2021-0014] This research was supported by European Urological Scholarship Programme,S-2021-0014.
dc.identifier.doi10.1007/s00345-023-04329-8
dc.identifier.eissn1433-8726
dc.identifier.issn0724-4983
dc.identifier.quartileQ2
dc.identifier.scopus2-s2.0-85148468237
dc.identifier.urihttps://doi.org/10.1007/s00345-023-04329-8
dc.identifier.urihttps://hdl.handle.net/20.500.14288/12647
dc.identifier.wos935355400001
dc.keywordsTesticular cancer
dc.keywordsRetroperitoneal lymph node dissection
dc.keywordsRobotic surgery
dc.keywordsPostchemotherapy
dc.keywordsMinimally invasive surgery
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofWorld Journal of Urology
dc.subjectUrology
dc.subjectNephrology
dc.titlePostchemotherapy robotic retroperitoneal lymph node dissection for non-seminomatous germ cell tumors in the lateral decubitus position: oncological and functional outcomes
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorKordan, Yakup
local.contributor.kuauthorKöseoğlu, Ersin
local.contributor.kuauthorEsen, Barış
local.contributor.kuauthorÖzkan, Arif
local.contributor.kuauthorKiremit, Murat Can
local.contributor.kuauthorEsen, Tarık
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit1KUH (KOÇ UNIVERSITY HOSPITAL)
local.publication.orgunit2KUH (Koç University Hospital)
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery055775c9-9efe-43ec-814f-f6d771fa6dee

Files